NAD+ Homeostasis and NAD+-Consuming Enzymes: Implications for Vascular Health
暂无分享,去创建一个
[1] Yu Wang,et al. Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] Rebecca A Dagg,et al. Targeting DNA damage response pathways in cancer , 2022, Nature Reviews Cancer.
[3] A. Tuttolomondo,et al. Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases , 2022, International journal of molecular sciences.
[4] M. Acosta-Martínez,et al. The PI3K/Akt Pathway in Meta-Inflammation , 2022, International journal of molecular sciences.
[5] R. Mazzucchelli,et al. NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer , 2022, Molecular Biology Reports.
[6] Ning Wang,et al. FBXW7 alleviates hyperglycemia-induced endothelial oxidative stress injury via ROS and PARP inhibition , 2022, Redox biology.
[7] R. Gesuita,et al. HtrA1 in Gestational Diabetes Mellitus: A Possible Biomarker? , 2022, Diagnostics.
[8] H. Tukachinsky,et al. Potent Uncompetitive Inhibitors of Nicotinamide N-Methyltransferase (NNMT) as In Vivo Chemical Probes. , 2022, Journal of medicinal chemistry.
[9] P. Lotufo,et al. Post-COVID syndrome, inflammation, and diabetes , 2022, Journal of Diabetes and its Complications.
[10] Dickson Donu,et al. Emerging Role of Nicotinamide Riboside in Health and Diseases , 2022, Nutrients.
[11] S. Rani,et al. Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders , 2022, Scientific Reports.
[12] Zhao-Qi Wang,et al. PARP1: Liaison of Chromatin Remodeling and Transcription , 2022, Cancers.
[13] M. Emanuelli,et al. Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms , 2022, Biomolecules.
[14] K. Zabłocki,et al. Lipopolysaccharide affects energy metabolism and elevates nicotinamide N-methyltransferase level in human aortic endothelial cells (HAEC). , 2022, The international journal of biochemistry & cell biology.
[15] D. Marzioni,et al. Natural and synthetic compounds in Ovarian Cancer: a focus on NRF2/KEAP1 pathway. , 2022, Pharmacological research.
[16] G. Balercia,et al. Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: a systematic review , 2022, Journal of hypertension.
[17] B. Xia,et al. Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy , 2022, Frontiers in Oncology.
[18] G. Kroemer,et al. NAD+ and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities , 2022, Journal of lipid and atherosclerosis.
[19] Changmei Yang,et al. Complex roles of nicotinamide N-methyltransferase in cancer progression , 2022, Cell Death & Disease.
[20] Linfeng Zou,et al. Nicotinic Acid Riboside Regulates Nrf-2/P62-Related Oxidative Stress and Autophagy to Attenuate Doxorubicin-Induced Cardiomyocyte Injury , 2022, BioMed research international.
[21] Nichola J. Conlon,et al. A systems-approach to NAD+ restoration. , 2022, Biochemical pharmacology.
[22] Paul S. Simone,et al. Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain , 2022, Nutrients.
[23] A. Sun,et al. The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential , 2021, Genes & diseases.
[24] Yu Wang,et al. Endothelial SIRT1 as a target for the prevention of arterial ageing: promises and challenges. , 2021, Journal of cardiovascular pharmacology.
[25] A. Santarelli,et al. Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review , 2021, Biomolecules.
[26] Fabio Marcheggiani,et al. CD93 a potential player in cytotrophoblast and endothelial cell migration , 2021, Cell and Tissue Research.
[27] R. Raju,et al. Regulation of NAD+ metabolism in aging and disease. , 2021, Metabolism: clinical and experimental.
[28] M. Emanuelli,et al. Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers , 2021, Cancers.
[29] Hening Lin,et al. Sirtuin Modulators in Cellular and Animal Models of Human Diseases , 2021, Frontiers in Pharmacology.
[30] Zeping Hu,et al. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing , 2021, Mechanisms of Ageing and Development.
[31] Yue Cheng,et al. Nicotinamide mononucleotide: An emerging nutraceutical against cardiac aging? , 2021, Current opinion in pharmacology.
[32] R. Schiffelers,et al. Esterase-Sensitive Prodrugs of a Potent Bisubstrate Inhibitor of Nicotinamide N-Methyltransferase (NNMT) Display Cellular Activity , 2021, Biomolecules.
[33] Gerard J. P. van Westen,et al. Potent Inhibition of Nicotinamide N-Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics , 2021, Journal of medicinal chemistry.
[34] M. Vaccarezza,et al. Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging , 2021, Aging medicine (Milton (N.S.W)).
[35] M. Emanuelli,et al. The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update , 2021, Biomolecules.
[36] I. Ahel,et al. Serine ADP-ribosylation in DNA-damage response regulation. , 2021, Current opinion in genetics & development.
[37] M. Emanuelli,et al. Nicotinamide N-methyltransferase in endothelium protects against oxidant stress-induced endothelial injury. , 2021, Biochimica et biophysica acta. Molecular cell research.
[38] S. Melov,et al. Apigenin restores endothelial function by ameliorating oxidative stress, reverses aortic stiffening, and mitigates vascular inflammation with aging. , 2021, American journal of physiology. Heart and circulatory physiology.
[39] R. Houtkooper,et al. NAD+ homeostasis in human health and disease , 2021, EMBO molecular medicine.
[40] R. W. Sabnis. Novel Pyrimidine-5-carboxamide Compounds as NNMT Inhibitors for Treating Diabetes. , 2021, ACS medicinal chemistry letters.
[41] H. Schreuder,et al. Novel Inhibitors of Nicotinamide-N-Methyltransferase for the Treatment of Metabolic Disorders , 2021, Molecules.
[42] Qiu-zhen Lin,et al. NAD+ and Cardiovascular Diseases. , 2021, Clinica chimica acta; international journal of clinical chemistry.
[43] M. Fraga,et al. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation , 2021, Molecular metabolism.
[44] M. Emanuelli,et al. Macrocyclic peptides as allosteric inhibitors of nicotinamide N-methyltransferase (NNMT) , 2020, RSC chemical biology.
[45] E. Verdin,et al. NAD+ metabolism and its roles in cellular processes during ageing , 2020, Nature Reviews Molecular Cell Biology.
[46] Mark S. Schmidt,et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages , 2020, Nature Metabolism.
[47] K. Zabłocki,et al. Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N‐methyltransferase level in endothelial cells , 2020, Journal of applied toxicology : JAT.
[48] M. Grosicki,et al. Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium , 2020, Oxidative medicine and cellular longevity.
[49] E. Verdin,et al. Clinical Evidence for Targeting NAD Therapeutically , 2020, Pharmaceuticals.
[50] N. Takahashi,et al. Beneficial effects of nicotinamide on hypertensive mice with impaired endothelial nitric oxide function , 2020, Journal of experimental nephrology.
[51] Simone Brogi,et al. Role of hydrogen sulfide in cardiovascular ageing. , 2020, Pharmacological research.
[52] Simon J. Allison,et al. Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target. , 2020, Biochemical Society transactions.
[53] E. Slominska,et al. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. , 2020, Biochemical pharmacology.
[54] J. Pollock,et al. Sirt1 during Childhood is Associated with Microvascular Function Later in Life. , 2020, American journal of physiology. Heart and circulatory physiology.
[55] Xuben Yu,et al. Sirtuins family as a target in endothelial cell dysfunction: implications for vascular ageing , 2020, Biogerontology.
[56] D. Sinclair,et al. Administration of Nicotinamide Mononucleotide (NMN) Reduces Metabolic Impairment in Male Mouse Offspring from Obese Mothers , 2020, Cells.
[57] A. Daiber,et al. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. , 2020, Free radical biology & medicine.
[58] T. Kiss,et al. Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects , 2020, GeroScience.
[59] L. Altucci,et al. Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence , 2020, Epigenetics.
[60] J. Auwerx,et al. NAD+ homeostasis in health and disease , 2020, Nature Metabolism.
[61] L. Mazzanti,et al. A 25-Year Long Journey into the World of NO , 2020 .
[62] F. Braet,et al. Actin‐spectrin scaffold supports open fenestrae in liver sinusoidal endothelial cells , 2019, Traffic.
[63] Cory B. Giles,et al. Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects , 2019, GeroScience.
[64] T. Kiss,et al. Role of endothelial NAD+ deficiency in age-related vascular dysfunction. , 2019, American journal of physiology. Heart and circulatory physiology.
[65] T. Kiss,et al. Nicotinamide mononucleotide (NMN) treatment attenuates oxidative stress and rescues angiogenic capacity in aged cerebromicrovascular endothelial cells: a potential mechanism for the prevention of vascular cognitive impairment , 2019, GeroScience.
[66] S. Rani,et al. High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT). , 2019, Journal of medicinal chemistry.
[67] T. Kiss,et al. Nicotinamide mononucleotide (NMN) supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses and improves cognitive function in aged mice , 2019, Redox biology.
[68] P. Sachdev,et al. The Plasma NAD+ Metabolome Is Dysregulated in “Normal” Aging , 2019, Rejuvenation research.
[69] Yu Wang,et al. Endothelial SIRT1 prevents age-induced impairment of vasodilator responses by enhancing the expression and activity of soluble guanylyl cyclase in smooth muscle cells , 2018, Cardiovascular research.
[70] W. Ying,et al. NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications. , 2018, Antioxidants & redox signaling.
[71] B. Ferguson,et al. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart , 2018, International journal of molecular sciences.
[72] A. Donato,et al. Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease , 2018, Circulation research.
[73] G. Hong,et al. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis , 2018, Free radical biology & medicine.
[74] L. Ferrucci,et al. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.
[75] T. Papenfuss,et al. CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions , 2018, Front. Immunol..
[76] L. Guarente,et al. Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging , 2018, Cell.
[77] D. Sinclair,et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. , 2018, Cell metabolism.
[78] Mark S. Schmidt,et al. Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice. , 2018, Cell metabolism.
[79] J. Zweier,et al. Characterization of CD38 in the major cell types of the heart: endothelial cells highly express CD38 with activation by hypoxia-reoxygenation triggering NAD(P)H depletion. , 2018, American journal of physiology. Cell physiology.
[80] H. Dihazi,et al. Vascular Biology and Microcirculation Endothelial dysfunction is a superinducer of syndecan-4 : fibrogenic role of its ectodomain , 2018 .
[81] J. Baur,et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. , 2017, Cell metabolism.
[82] S. Watowich,et al. Selective and membrane‐permeable small molecule inhibitors of nicotinamide N‐methyltransferase reverse high fat diet‐induced obesity in mice , 2018, Biochemical pharmacology.
[83] M. Mattson,et al. NAD+ in Aging: Molecular Mechanisms and Translational Implications. , 2017, Trends in molecular medicine.
[84] Dong Woon Kim,et al. CR6-Interacting Factor 1 Deficiency Impairs Vascular Function by Inhibiting the Sirt1-Endothelial Nitric Oxide Synthase Pathway. , 2017, Antioxidants & redox signaling.
[85] P. Pissios. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme , 2017, Trends in Endocrinology & Metabolism.
[86] M. Mozzon,et al. Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. , 2017, Food chemistry.
[87] M. Emanuelli,et al. Molecular analysis of endometrial inflammation in preterm birth. , 2017, Cellular and Molecular Biology.
[88] E. Mikó,et al. Metabolic roles of poly(ADP-ribose) polymerases. , 2017, Seminars in cell & developmental biology.
[89] R. Breyer,et al. Niacin Promotes Cardiac Healing after Myocardial Infarction through Activation of the Myeloid Prostaglandin D2 Receptor Subtype 1 , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[90] S. Imai,et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. , 2016, Cell metabolism.
[91] D. Sinclair,et al. Why NAD(+) Declines during Aging: It's Destroyed. , 2016, Cell metabolism.
[92] Pei Wang,et al. NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair , 2016, Journal of cardiovascular pharmacology.
[93] D. Seals,et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice , 2016, Aging cell.
[94] B. Sitek,et al. Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor–Deficient Mice: A Comparison with Nicotinic Acid , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[95] Ulrich Sack,et al. Nicotinamide: a vitamin able to shift macrophage differentiation toward macrophages with restricted inflammatory features , 2015, Innate immunity.
[96] A. Kaczor,et al. Identification of a biochemical marker for endothelial dysfunction using Raman spectroscopy. , 2015, The Analyst.
[97] J. Baur,et al. Increasing NAD Synthesis in Muscle via Nicotinamide Phosphoribosyltransferase Is Not Sufficient to Promote Oxidative Metabolism* , 2014, The Journal of Biological Chemistry.
[98] Evan G. Williams,et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. , 2014, Cell metabolism.
[99] P. Little,et al. Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications , 2014, Medicinal research reviews.
[100] W. Kraus,et al. PARP-1 and gene regulation: progress and puzzles. , 2013, Molecular aspects of medicine.
[101] L. Virág,et al. Poly(ADP-ribose) signaling in cell death. , 2013, Molecular aspects of medicine.
[102] D. Seals,et al. Life‐long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice , 2013, Aging cell.
[103] P. Puigserver,et al. The sirtuin family's role in aging and age-associated pathologies. , 2013, The Journal of clinical investigation.
[104] C. Cantó,et al. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. , 2012, Cell metabolism.
[105] V. Napolioni,et al. Population variability in CD38 activity: correlation with age and significant effect of TNF-α -308G>A and CD38 184C>G SNPs. , 2012, Molecular genetics and metabolism.
[106] Alexander S. Banks,et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). , 2011, Molecular cell.
[107] S. Tunaru,et al. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. , 2011, Trends in pharmacological sciences.
[108] J. Sikora,et al. 1-methylnicotinamide effects on the selected markers of endothelial function, inflammation and haemostasis in diabetic rats. , 2010, European journal of pharmacology.
[109] W. Kraus,et al. Clickable NAD analogues for labeling substrate proteins of poly(ADP-ribose) polymerases. , 2010, Journal of the American Chemical Society.
[110] Yu Wang,et al. SIRT1 Promotes Proliferation and Prevents Senescence Through Targeting LKB1 in Primary Porcine Aortic Endothelial Cells , 2010, Circulation research.
[111] Z. Ďuračková,et al. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats , 2009, Pharmacological reports : PR.
[112] C. Brenner,et al. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. , 2008, Annual review of nutrition.
[113] C. Szabó,et al. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. , 2008, The American journal of pathology.
[114] E. Hoffman,et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. , 2008, Developmental cell.
[115] E. Slominska,et al. 1-Methylnicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages , 2008, Archivum Immunologiae et Therapiae Experimentalis.
[116] J. Borén,et al. PARP1 is required for adhesion molecule expression in atherogenesis. , 2007, Cardiovascular research.
[117] Cuk-Seong Kim,et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase , 2007, Proceedings of the National Academy of Sciences.
[118] W. Buczko,et al. 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway , 2007, British journal of pharmacology.
[119] C. Szabó,et al. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. , 2007, Cardiovascular drug reviews.
[120] R. Menon,et al. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. , 2007, International journal of clinical pharmacology and therapeutics.
[121] G. Pierce,et al. Direct Evidence of Endothelial Oxidative Stress With Aging in Humans: Relation to Impaired Endothelium-Dependent Dilation and Upregulation of Nuclear Factor-&kgr;B , 2007, Circulation research.
[122] A. Boulares,et al. Poly(ADP-Ribose) Polymerase Inhibition Reduces Atherosclerotic Plaque Size and Promotes Factors of Plaque Stability in Apolipoprotein E–Deficient Mice: Effects on Macrophage Recruitment, Nuclear Factor-&kgr;B Nuclear Translocation, and Foam Cell Death , 2007, Circulation.
[123] A. Reiss,et al. Recent insights into the role of prostanoids in atherosclerotic vascular disease. , 2006, Current vascular pharmacology.
[124] Emilio Clementi,et al. Calorie Restriction Promotes Mitochondrial Biogenesis by Inducing the Expression of eNOS , 2005, Science.
[125] L. Ghiadoni,et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. , 2005, American journal of hypertension.
[126] C. Brenner,et al. Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans , 2004, Cell.
[127] R. Schwartz,et al. Pellagra: Dermatitis, dementia, and diarrhea , 2004, International journal of dermatology.
[128] D. Sinclair,et al. Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1* , 2002, The Journal of Biological Chemistry.
[129] W. Quist,et al. Poly(ADP-Ribose) Polymerase Is Activated in Subjects at Risk of Developing Type 2 Diabetes and Is Associated With Impaired Vascular Reactivity , 2002, Circulation.
[130] S. Snyder,et al. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[131] K. Murthy,et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation , 2001, Nature Medicine.
[132] G. Poirier,et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.
[133] J. Ménissier-de murcia,et al. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. , 1999, American journal of human genetics.
[134] N. Berger. Poly(ADP-ribose) in the cellular response to DNA damage. , 1985, Radiation research.
[135] A. Harper,et al. Niacin-tryptophan relationships for evaluating niacin equivalents. , 1981, The American journal of clinical nutrition.
[136] M. Powanda,et al. NAD synthesis in animal tissues. , 1968, The Journal of vitaminology.